Data from an open-label trial showed that foralumab treatment eased fatigue and lessened disability for some people with ...

A new study led by researchers at Mass General Brigham suggests a nasal spray developed to target neuroinflammation could one ...

Modulating the neuroinflammatory response using the nasal spray, Izzy said ... The study examines the monoclonal antibody Foralumab, made by Tiziana, which has been tested in clinical trials ...

When delivered intravenously, foralumab kills T cells, but when introduced into the mucosa, either orally or intranasally, it stimulates T-regs instead. For trials of AD and other disorders, the ...

This comprehensive study demonstrated that nasal foralumab was safe, induced potent regulatory immune responses, reduced microglial activation, and stabilized clinical progression in patients ...

This comprehensive study demonstrated that nasal foralumab was safe, induced potent regulatory immune responses, reduced microglial activation, and stabilized clinical progression in patients ...

Ten patients with na-SPMS, who continued to progress despite B-cell therapy, were treated with nasal foralumab for a minimum of six months. No serious or severe treatment-related adverse events ...